Source Post
Buy Heavy! This is How I Found the Next 158% Stock
Aug 19, 2025
The creator discusses Novo Nordisk (NVO) and Hims & Hers (HIMS), highlighting recent FDA approval for Novo Nordisk's drug for liver disease and the potential for a rebound. The video also touches on the impact of generic GLP-1 drugs and their potential as catalysts for both companies.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.